Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
De Angelis F, Cameron JR, Eshaghi A, Parker R, Connick P, Stutters J, Plantone D, Doshi A, John N, Williams T, Calvi A, MacManus D, Barkhof F, Chandran S, Weir CJ, Toosy A, Chataway J; MS-SMART trial investigators. De Angelis F, et al. Among authors: barkhof f. J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801. doi: 10.1136/jnnp-2024-334801. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39694820
Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
Kappos L, Edan G, Freedman MS, Hartung HP, Montalbán X, Barkhof F, Koelbach R, MacManus DG, Wicklein EM; BENEFIT and BENEFIT 15 Study Groups. Kappos L, et al. Among authors: barkhof f. J Neurol. 2024 Jul;271(7):4599-4609. doi: 10.1007/s00415-024-12417-x. Epub 2024 May 10. J Neurol. 2024. PMID: 38730097 Free PMC article. Clinical Trial.
Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
Brownlee WJ, Vidal-Jordana A, Shatila M, Strijbis E, Schoof L, Killestein J, Barkhof F, Bollo L, Rovira A, Sastre-Garriga J, Tintore M, Rocca MA, Esposito F, Azzimonti M, Filippi M, Bodini B, Lazzarotto A, Stankoff B, Montalban X, Toosy AT, Thompson AJ, Ciccarelli O; MAGNIMS Study Group. Brownlee WJ, et al. Among authors: barkhof f. Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145. Online ahead of print. Ann Neurol. 2024. PMID: 39605172
Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation.
Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, Kivipelto M, Jessen F, Hanseeuw B, Boada M, Barkhof F, Nordberg A, Froelich L, Waldemar G, Frederiksen KS, Padovani A, Planche V, Rowe C, Bejanin A, Ibanez A, Cappa S, Caramelli P, Nitrini R, Allegri R, Slachevsky A, de Souza LC, Bozoki A, Widera E, Blennow K, Ritchie C, Agronin M, Lopera F, Delano-Wood L, Bombois S, Levy R, Thambisetty M, Georges J, Jones DT, Lavretsky H, Schott J, Gatchel J, Swantek S, Newhouse P, Feldman HH, Frisoni GB. Dubois B, et al. Among authors: barkhof f. JAMA Neurol. 2024 Dec 1;81(12):1304-1311. doi: 10.1001/jamaneurol.2024.3770. JAMA Neurol. 2024. PMID: 39483064
Amyloid-Related Imaging Abnormalities in Clinical Trials of Gantenerumab in Early Alzheimer Disease.
Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Salloway S, et al. Among authors: barkhof f. JAMA Neurol. 2024 Nov 18:e243937. doi: 10.1001/jamaneurol.2024.3937. Online ahead of print. JAMA Neurol. 2024. PMID: 39556389 Free PMC article.
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Depressive symptoms predict cognitive decline and dementia in older people independently of cerebral white matter changes: the LADIS study.
Verdelho A, Madureira S, Moleiro C, Ferro JM, O'Brien JT, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Erkinjuntti T, Inzitari D; LADIS Study. Verdelho A, et al. J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1250-4. doi: 10.1136/jnnp-2012-304191. Epub 2013 May 28. J Neurol Neurosurg Psychiatry. 2013. PMID: 23715914
More Than the Sum of Its Parts: Disrupted Core Periphery of Multiplex Brain Networks in Multiple Sclerosis.
Pontillo G, Prados F, Wink AM, Kanber B, Bisecco A, Broeders TAA, Brunetti A, Cagol A, Calabrese M, Castellaro M, Cocozza S, Colato E, Collorone S, Cortese R, De Stefano N, Douw L, Enzinger C, Filippi M, Foster MA, Gallo A, Gonzalez-Escamilla G, Granziera C, Groppa S, Harbo HF, Høgestøl EA, Llufriu S, Lorenzini L, Martinez-Heras E, Messina S, Moccia M, Nygaard GO, Palace J, Petracca M, Pinter D, Rocca MA, Strijbis E, Toosy A, Valsasina P, Vrenken H, Ciccarelli O, Cole JH, Schoonheim MM, Barkhof F; MAGNIMS study group. Pontillo G, et al. Among authors: barkhof f. Hum Brain Mapp. 2025 Jan;46(1):e70107. doi: 10.1002/hbm.70107. Hum Brain Mapp. 2025. PMID: 39740239 Free PMC article.
1,520 results